Pharmstandard: Difference between revisions
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Infobox company | |
{{Infobox company | |
||
name = JSC Pharmstandard| |
name = JSC Pharmstandard| |
||
type = [[Public company|Public]] ([[Joint-stock company| |
type = [[Public company|Public]] ([[Joint-stock company|JSC]]) | |
||
traded_as = | |
traded_as = | |
||
company_logo = [[File:Pharmstandard.svg|120px]]| |
company_logo = [[File:Pharmstandard.svg|120px]]| |
||
Revision as of 19:26, 29 August 2017
 | |
| Company type | Public (JSC) |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 2003 |
| Headquarters | Dolgoprudny, Russia |
Key people | Viktor Vladimirovich Kharitonin,(Chairman) Igor Konstantinovich Krylov, (CEO) |
| Products | Remedies |
| Revenue |  US$ 1.6 billion (2012) |
15,515,504,000 Russian ruble (2016)  | |
| US$ 321.1 million (2012) | |
| Total assets | 94,509,570,000 Russian ruble (2016) |
Number of employees | 5,001 |
| Website | pharmstd.com |
JSC Pharmstandard (Russian: ПАО «Фармстандарт», PAO "Farmstandart") is the leading Russian pharmaceutical company, it is headquartered in Dolgoprudny.
Pharmstandard portfolio includes over 200 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer, etc. Over 90 products offered by Pharmstandard are included in the List of Vital Pharmaceutical Products.[1]
The company has six manufacturing facilities located in Moscow, Ufa, Nizhny Novgorod, Kursk, Tomsk and Tyumen.
Pharmstandard was delisted from the London and Moscow stock exchanges in 2017.[2][3]
References
- ^ https://www.youtube.com/watch?v=tdTUwbhkPfc
- ^ "BRIEF-Pharmstandard shares to be delisted as of March 24 - Moscow Exchange". Reuters. 17 February 2017. Retrieved 23 April 2017.
- ^ "Об исключении ценных бумаг из Списка ценных бумаг, допущенных к торгам, и о прекращении торгов ценными бумагами". Московская Биржа. Retrieved 28 August 2017.
